Zhejiang Heren Technology Co., Ltd. (hereinafter referred to as “Heren Technologyâ€) launched a listing application on the GEM of the Shenzhen Stock Exchange on September 30, 2016. The company's public offering of this company does not exceed 20 million shares, and the number of online issuances is 20 million shares, accounting for 100% of the number of shares issued this time. Heren Technology expects to raise a total of 251 million yuan. After deducting the issuer's estimated issuance expenses, it is estimated that the net proceeds will be 260 million yuan.
According to the economic report, the predecessor of Heren Technology is limited. In October 2013, Heren Limited was changed to Heren Technology. According to the proposed prospectus, from December 2010 to August 2012, Zhongkong Research Institute held a capital contribution of RMB 1.8 million, which accounted for 9% of the registered capital of the company. But the strange thing is that the proposed prospectus does not disclose how the Zhongkong Research Institute has entered and is limited. Before the overall restructuring, in August 2013, the 9% equity of Heren Technology held by Zhongkong Research Institute suddenly disappeared. Where did the equity go? The proposed prospectus did not give relevant information.
At the trial meeting on May 13, the audit committee inquired about the historical relationship between the company and the central control group. The IEC said that according to the application materials, Yang Yibing, the actual controller of the company, had served as the central control information. The IEC has asked whether the personnel, technology, assets and business of Renren Technology are independent of the central control information, and whether the issuer has lost state capital in the course of historical evolution.
According to the Securities Market Weekly report, from 2013 to 2015, the sales of the top five customers of Heren Technology accounted for 53.67%, 85.19% and 58.22% of the operating revenue respectively, and the customer concentration was higher. More precisely, the first largest customer accounted for a relatively high proportion. According to the prospectus, in 2013, the first largest customer of Heren Technology was Zhongkong Information, with a sales income of 33.79 million yuan, accounting for 24.16%; in 2014, the largest customer of Renren Technology was the People's Liberation Army General Hospital, with a sales income of 132 million yuan. The proportion was 58.25%; in 2015, the largest customer was still the People's Liberation Army General Hospital, with sales revenue of 89 million yuan, accounting for 39.37%.
According to the investor report, the existing shareholders of Heren Technology are Wuyuan Investment, Yuhong Investment, Jinshiyu, Lei Shi Ruifeng, Lei Shi Yuhua and Shengjing Fortune. Jin Shiyi is the grandson of the company's IPO sponsor CITIC Securities. Jin Shiyi’s shareholding in Heren Technology was acquired on October 18, 2013. The sponsors rushed into the proposed company and expressed doubts about the neutrality of the sponsors.
The reporter sent an interview letter to the office of the Board of Directors of Heren Technology on the above issues, and did not receive a reply as of the press release.
Medical information service company plans to land on the GEM
According to the prospectus, Heren Technology is a high-tech enterprise focusing on R&D, sales, implementation integration and service support of medical institutions' clinical medical management information systems and digital scene application systems. The company takes the electronic medical record system and its extended application as the core, the clinical diagnosis and treatment information integration platform as the link, the medical institution management information system as the extension application, the digital scene application as the supplement, and the information security and system operation and maintenance service as the guarantee to form. The digital hospital's overall solution based on the information application needs of medical institutions, and constantly improve and expand related business areas.
The controlling shareholder of the company is Wuyuan Investment, and the actual controllers are Yang Yibing and Yang Bo. Yang Yibing is the chairman and general manager of the company. Yang Bo is currently the director and deputy general manager of the company.
On December 25, 2013, Yang Yibing and Yang Bo signed the "Consensus Action Agreement" to jointly guarantee Yang Yibing and Yang Bo as the actual controllers of the actual control position of Heren Technology. Yang Yibing and Yang Bo controlled the 84.55% stake in Renzhong Technology through Wuyuan Investment and Yuhong Investment, which was the actual controller of the company.
The company intends to list on the GEM of the Shenzhen Stock Exchange. It is estimated that the total amount of funds raised will be 251 million yuan. After deducting the issuer's estimated issuance expenses, the net proceeds are expected to be 260 million yuan. It is used in medical information product production base construction projects, enterprise research institute construction projects, marketing network projects, supplementary working capital and repayment of bank loans.
Furosemide Inj,Methyldopa Tablets,Lisinopril Dosage Range,Methyldopa 250 Mg Tablet
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com